After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Still, Hims & Hers has other avenues to explore. The company could continue to offer more personalized semaglutide formulations and shift its focus to older generic weight-loss drugs. Additionally ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

But with GLP-1 sales vanishing, Hims is left banking on generic weight-loss pills and its core business in hair-loss and ED treatments. While that business is solid, it doesn't justify the lofty ...

The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are ...

Hims also launched an oral weight-loss regimen in late 2023. These pills combine bupropion, metformin, topiramate, vitamin B12, and naltrexone. Three of the four are treatments for other diseases ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...